Table 1.

Patient characteristics and treatment at diagnosis (n = 188).

A: 25 mg n = 94 (100%)B: 5 mg n = 94 (100%)
Male sex56 (60)60 (64)
Age, yearsMedian (range)58 (33–71)58 (30–72)
≤6572 (77)72 (77)
SubtypeIgG56 (60)54 (58)
IgA18 (20)16 (17)
LC20 (21)22 (23)
Other0 (0)2 (2)
Durie Salmon stageI8 (9)4 (4)
II8 (9)13 (14)
III78 (82)77 (82)
A78 (83)78 (83)
B16 (17)16 (17)
ISS-Stage150 (54)53 (57)
225 (27)19 (20)
318 (19)22 (23)
FISH cytogeneticsStandard risk25 (27)21 (22)
High riska15 (16)14 (15)
Unknown54 (57)59 (63)
R-ISS stage121(22)17 (18)
238 (41)31 (33)
33 (3)9 (10)
Unknown32(34)37 (39)
Chronic kidney disease, stage1+268 (76)63 (72)
37 (8)12 (14)
44 (5)4 (5)
5, dialysis10 (11)8 (9)
Induction therapy containing bortezomibYes76 (81)80 (85)
No18 (19)14 (15)
Number of induction cyclesMedian (range)3 (1–6)3 (1–6)
High-dose melphalan regimen [mg/m2]20057 (61)45 (48)
200 Tandem22 (22)35 (37)
100 Tandem15 (16)14 (15)
Remission after HDCTCR14 (16)24 (28)
vgPR45 (49)38 (37)
PR28 (29)30 (32)
MR/SD7 (6)2 (3)
Diagnosis to baseline, monthsMedian (range)10 (7–19)11 (5–21)
ASCT to baseline (days)Median (range)114 (72–195)117 (61–176)
  • Abbreviations: LC, Light chain; MR/SD, minimal response/stable disease.

  • a+1q (>3), t(4;14), t(14;16), del17p.